Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Plasma cell 2Lymphoid 1CNS 1

Conditions

Glioblastoma 276Brain Neoplasms 169Glioma 139Central Nervous System Neoplasms 85Gliosarcoma 79Astrocytoma 74Neuroblastoma 64Oligodendroglioma 42Neoplasms 40Breast Neoplasms 38Recurrence 37Carcinoma, Non-Small-Cell Lung 31Medulloblastoma 27Melanoma 26Ovarian Neoplasms 24Lymphoma 21Diffuse Intrinsic Pontine Glioma 21Sarcoma 19Neoplasm Metastasis 19Lung Neoplasms 18Colorectal Neoplasms 17Rhabdomyosarcoma 16Osteosarcoma 16Meningeal Carcinomatosis 15Ependymoma 15Pancreatic Neoplasms 14Meningioma 14Sarcoma, Ewing 13Stomach Neoplasms 12Esophageal Neoplasms 12

Interventions

repotrectinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solitary Fibrous Tumors × CNS × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡